Homepage
Catalog of Screening Compounds Screening Libraries Focused and Target Libraries Active Reference Sets Diversity Libraries
Screening Compounds Building blocks
Drug Discovery Services Custom Chemistry Medicinal chemistry In silico Drug Design (CADD) Discovery Biology Animal Models Toxicology and Safety ADME, DMPK Chemistry, Manufacturing and Controls
Company News & Media Contact us For suppliers Trends in discovery compounds
Homepage > Company > Media > Pharma News > 2016

Pharma News, 2016

Durvalumab granted breakthrough therapy designation by US FDA for treatment of patients with PD-L1 positive urothelial bladder cancer
Durvalumab granted breakthrough therapy designation by US FDA for treatment of patients with PD-L1 positive urothelial bladder cancer
AstraZeneca and MedImmune, its global biologics research and development arm, today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for du...
New Class Of Drug Raises Hope For Blood Cancer Patients
New Class Of Drug Raises Hope For Blood Cancer Patients
NEW YORK.
Flexion's pain drug succeeds in study, shares soar
Flexion's pain drug succeeds in study, shares soar
Flexion Therapeutics Inc's pain drug was found to be effective in a late-stage study, taking the company one step closer to its first ever U.
WHO seeks $56 million for plan to combat Zika virus
WHO seeks $56 million for plan to combat Zika virus
The World Health Organization (WHO) said on Wednesday that $56 million would be needed until June to fund a strategy to combat the Zika virus which has spread to 39 countries and has been link...
U.S. FDA Approves Two Supplemental Indications for Harvoni® in Chronic Hepatitis C Patients With Advanced Liver Disease
U.S. FDA Approves Two Supplemental Indications for Harvoni® in Chronic Hepatitis C Patients With Advanced Liver Disease
FOSTER CITY, Calif.
Pfizer to Pay $785 Million to Settle Medicaid Claims
Pfizer to Pay $785 Million to Settle Medicaid Claims
Drugmaker Pfizer Inc.
US FDA refuses to approve Merck's Zetia and Vytorin medicines
US FDA refuses to approve Merck's Zetia and Vytorin medicines
                                   Zetiia                                                              VytorinThe US Food and Drug Administration (...
Biocon's Rosuvastatin Calcium tablets get EU approval to treat hyperlipidemia
Biocon's Rosuvastatin Calcium tablets get EU approval to treat hyperlipidemia
Indian biopharmaceutical company Biocon has received approval from the European Commission for its Rosuvastatin Calcium tablets to treat hyperlipidemia or mixed dyslipidemia.
Sun Pharma calls off Merck deal
Sun Pharma calls off Merck deal
Our Special Correspondent, Mumbai.
FDA grants orphan status for Amarantus' eltoprazine to treat PD-LID
FDA grants orphan status for Amarantus' eltoprazine to treat PD-LID
The US Food and Drug Administration (FDA) has granted orphan drug designation for Amarantus BioScience Holdings' (AMBS') eltoprazine to treat Parkinson's disease levodopa-i...
Glaxo fined £37.6m for 'illegal behaviour' over Seroxat deals
Glaxo fined £37.6m for 'illegal behaviour' over Seroxat deals
GlaxoSmithKline has been fined £37.
Teva Shares Plunge as Sales of Copaxone Disappoint
Teva Shares Plunge as Sales of Copaxone Disappoint
Teva Pharmaceutical Industries Ltd.
Catalog of Screening Compounds Screening Libraries Screening Compounds Building blocks
Drug Discovery Services News & Media Contact us
Payment systems
Policies & Terms     ©2023 ChemDiv     ChemistryOnDemand